NextCure stock gained 2.1% in premarket trading following the announcement of positive Phase 1 dose-escalation data for its investigational cancer drug SIM0505 at the ASCO 2026 meeting. SIM0505 targets Cadherin-6 and aims to treat platinum-resistant ovarian cancer and uterine serous carcinoma, both with limited treatment options. Despite the positive clinical data, the stock remains in a strong downtrend, trading well below key moving averages, indicating ongoing bearish sentiment. Investors may watch for a move above resistance levels to confirm any meaningful recovery.
Diana Shipping Inc. has criticized Genco Shipping & Trading for changing its valuation methods to avoid engaging with Diana's $24.80 per share all-cash takeover offer. Diana argues it has consistently offered around 1.0x NAV based on broker valuation...
The HON Company has launched a new 12,000-square-foot flagship showroom in Chicago, designed as an immersive workplace and learning environment. The showroom integrates HON's portfolio across four zones—The Commons, The Sandbox, The Hub, and The Educ...
Medtronic reported adjusted earnings of $1.55 per share, slightly above estimates, and revenue rose 9.9% year-over-year to $9.81 billion, driven by strong cardiovascular segment growth. BTIG upgraded Medtronic from Neutral to Buy, citing accelerating...
The global market for non-invasive blood glucose monitoring devices, which measure blood sugar without needles, is projected to grow from $34.86 million in 2024 to $340.49 million by 2034, at a CAGR of 25.6%. Growth is fueled by the increasing diabet...
IBM has formed a strategic partnership with Google Cloud to accelerate AI adoption across industries like banking, retail, and telecom by launching a joint Google Cloud Practice. The collaboration aims to help customers deploy and manage AI at scale ...
